Predicting Clinical outcomes in cancer patients based on novel computational biology method of mapping the cancer mutanome

Background: Despite three FDA approved standard of care (SOC) therapeutics, 60% of patients with myelodysplastic syndromes (MDS) fail to achieve hematologic improvement and nearly all patients die of refractory disease.